This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.
Zimmer Biomet (ZBH) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet (ZBH) might have faced an upheaval in business, thanks to the global inflationary situation in terms of mounting labor and raw material costs, severe staffing shortages and supply issues.
Here's Why Investors Should Invest in Zimmer Biomet (ZBH) Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH) on strong elective procedure recovery and commercial execution.
AngioDynamics (ANGO) Q3 Earnings Lag Estimates, FY23 View Cut
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech and Med Device businesses in third-quarter fiscal 2023.
ZBH vs. LMAT: Which Stock Is the Better Value Option?
by Zacks Equity Research
ZBH vs. LMAT: Which Stock Is the Better Value Option?
QuidelOrtho (QDEL) Down 4.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
QuidelOrtho (QDEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why Investors Should Buy Zimmer Biomet (ZBH) Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH) on ongoing business recovery.
Zimmer Biomet (ZBH) Gains From Market Recovery, Global Growth
by Zacks Equity Research
Zimmer Biomet (ZBH) witnesses continued traction across hip products, including the G7 revision system and Avenir Complete primary hip.
ZBH vs. LMAT: Which Stock Is the Better Value Option?
by Zacks Equity Research
ZBH vs. LMAT: Which Stock Is the Better Value Option?
Zacks Industry Outlook Highlights Stryker, Zimmer Biomet and Haemonetics
by Zacks Equity Research
Stryker, Zimmer Biomet and Haemonetics have been highlighted in this Industry Outlook article.
Zimmer Biomet (ZBH) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Medical Products Stocks Navigating Industry Challenges
by Indrajit Bandyopadhyay
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should lend support to the Zacks Medical-Products industry. SYK, ZBH and HAE are well-poised to gain from the favorable factors.
STAAR Surgical (STAA) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Strong growth in EVO ICL units led by increased market adoption is likely to have driven STAAR Surgical's (STAA) Q4 revenues.
Zimmer Biomet (ZBH) Q4 Earnings Beat Estimates, Margins Up
by Zacks Equity Research
Each of Zimmer Biomet's (ZBH) geographic segments and product divisions record year-over-year sales growth at CER.
Zimmer Biomet (ZBH) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 2.73% and 3.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Zimmer Biomet (ZBH) Ahead of Earnings?
by Zacks Equity Research
Zimmer Biomet (ZBH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
What's in the Cards for Mesa Laboratories' (MLAB) Q3 Earnings?
by Zacks Equity Research
Continued strength in Mesa Laboratories' (MLAB) Clinical Genomics segment is expected to have driven up Q3 sales.
ZBH vs. ABT: Which Stock Is the Better Value Option?
by Zacks Equity Research
ZBH vs. ABT: Which Stock Is the Better Value Option?
BellRing Brands (BRBR) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
BellRing Brands (BRBR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zimmer Biomet (ZBH) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zimmer Biomet (ZBH) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Zimmer Biomet (ZBH) is expected to have witnessed continued recovery in its legacy business in the fourth quarter, despite the choppy market situation.
Here's Why Investors Should Retain Zimmer Biomet (ZBH) Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH) owing to ongoing business recovery from the COVID-led pandemic impact.
Zimmer Biomet (ZBH) Procedure Volume Gain Aids Amid FX Hurdles
by Zacks Equity Research
Zimmer Biomet (ZBH) continues to face significant challenges in terms of unfavorable foreign exchange, supply, inflation and staffing shortage.
Zimmer Biomet (ZBH) Q3 Earnings Beat, Gross Margin Falls
by Zacks Equity Research
Each of Zimmer Biomet's (ZBH) geographic segments and product divisions barring S.E.T. and "Other" record year-over-year sales growth at CER.
Zimmer Biomet (ZBH) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 1.28% and 2.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Envista (NVST) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Envista (NVST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.